[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Special Article
November 24, 2008

Assessing New Biomarkers and Predictive Models for Use in Clinical PracticeA Clinician's Guide

Author Affiliations

Author Affiliations: Screening and Test Evaluation Program, School of Public Health (Mr McGeechan and Drs Macaskill and Irwig) and Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute (Dr Liew), University of Sydney, Sydney, Australia; and Centre for Eye Research Australia, University of Melbourne, Royal Victoria Eye and Ear Hospital, Melbourne, Australia, and Singapore Eye Research Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (Dr Wong).

Arch Intern Med. 2008;168(21):2304-2310. doi:10.1001/archinte.168.21.2304
Abstract

New biomarkers and predictive models that aim to improve the identification of people at risk of cardiovascular disease are constantly proposed. Clinicians need to be aware of the various methods used to assess these biomarkers and models and how these should be interpreted. New biomarkers and models are assessed in terms of their contribution to global fit, discrimination, calibration, and reclassification. These measures, when used in isolation, do not address the clinically important questions of whether the new model predicts risk more accurately than existing models and whether the risks predicted for individuals are sufficiently different to warrant a change in treatment decisions. We recommend that these measures be supplemented with graphical displays such as a calibration plot for the Hosmer-Lemeshow test and a scatterplot of the risks predicted by the models being compared. We encourage researchers to report such analyses from studies on the clinical utility of new biomarkers because this information is pertinent for the clinician who must decide whether to test for a new biomarker in their clinical practice.

×